SRRK vs. PRME, CGEM, RLAY, AUTL, MESO, IMTX, PROK, HUMA, CRGX, and RGNX
Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Prime Medicine (PRME), Cullinan Therapeutics (CGEM), Relay Therapeutics (RLAY), Autolus Therapeutics (AUTL), Mesoblast (MESO), Immatics (IMTX), ProKidney (PROK), Humacyte (HUMA), CARGO Therapeutics (CRGX), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry.
Prime Medicine (NYSE:PRME) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk.
Scholar Rock has higher revenue and earnings than Prime Medicine. Scholar Rock is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
Prime Medicine has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Prime Medicine presently has a consensus target price of $15.09, indicating a potential upside of 123.90%. Scholar Rock has a consensus target price of $25.17, indicating a potential upside of 137.20%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than Prime Medicine.
Prime Medicine's return on equity of -94.20% beat Scholar Rock's return on equity.
70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 24.3% of Prime Medicine shares are owned by company insiders. Comparatively, 26.2% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Prime Medicine had 4 more articles in the media than Scholar Rock. MarketBeat recorded 12 mentions for Prime Medicine and 8 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.61 beat Prime Medicine's score of 0.58 indicating that Prime Medicine is being referred to more favorably in the media.
Scholar Rock received 136 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 72.22% of users gave Prime Medicine an outperform vote while only 63.40% of users gave Scholar Rock an outperform vote.
Summary
Scholar Rock beats Prime Medicine on 11 of the 17 factors compared between the two stocks.
Get Scholar Rock News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scholar Rock Competitors List
Related Companies and Tools
